**07. Update on clinical and programmatic management of MDR-TB and XDR-TB**

**Wednesday, 29 October 2014, 09:00 - 17:00**

**Room 133/134**

<table>
<thead>
<tr>
<th><strong>Type</strong></th>
<th>Post-graduate Course</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Track</strong></td>
<td>Tuberculosis</td>
</tr>
<tr>
<td><strong>Topic</strong></td>
<td>Medical management of TB and drug resistant TB</td>
</tr>
<tr>
<td><strong>Duration</strong></td>
<td>Full-day</td>
</tr>
<tr>
<td><strong>Max attendees</strong></td>
<td>75</td>
</tr>
</tbody>
</table>

**Description**

MDR- and XDR-TB pose a significant threat to TB control and challenge clinicians and programme managers world-wide with complexities in diagnosis, treatment, case management and infection control. This course addresses challenges of DR-TB management by presenting updated epidemiologic and surveillance data, and providing clinical and programmatic strategies relevant to a wide-range of practitioners based on the most recent international policies and standards of care. Cutting edge strategies for care and programmatic management of DR-TB will be presented to promote best practices globally.

**Target audience**

National TB and HIV programme managers, lung health specialists, TB & HIV clinicians, epidemiologists, international tuberculosis consultants, laboratory scientists, microbiologists, promoters and deliverers of community-based health care.

**Objectives**

1. To update global epidemiology of DR-TB and present principles of MDR-TB prevention, diagnosis, and treatment
2. To present recent advances in rapid diagnosis of drug-resistance and to discuss their clinical application
3. To discuss evidence-based management and controversial issues in the treatment of MDR/XDR-TB
4. To present cutting edge strategies for the management of MDR/XDR-TB including new drugs and diagnostic tools
5. To introduce community-based programmatic management of MDR-TB and discuss prevention strategies

**Keywords**

MDR-TB; XDR-TB; Management; Update; Diagnosis; Treatment

**Coordinator(s)**

Sundari Mase (USA), Ernesto Jaramillo (Switzerland)

**Chair(s)**

Ignacio Monedero (Spain), Jose Caminero Luna (Spain)

**Presentations**

1. MDR-TB/XDR-TB global epidemiology (including HIV-coinfecion)
   Dennis Falzon (Switzerland)
2. Principles of MDR-TB management
   Chen-yuan Chiang (Taiwan)
3. Rapid diagnostics tests: a laboratory based perspective
   Christopher Gilpin (Switzerland)
4. Treatment of MDR-TB: principles and controversial issues
   Jose Caminero Luna (Spain)
5. Pharmacovigilance and management of adverse drug effects
   Michael Rich (USA)
   H. Simon Schaaf (South Africa)
7. Special situations: HIV coinfection and pregnancy
   Jennifer Furin (USA)
8. Surgery in the management of MDR-TB
   Andrey Maryandyshev (Russian Federation)
9. Update in MDR-TB studies (9 month short course regimen)
   Armand Van Deun (Belgium), Arnaud Trebucq (France)
10. Introducing bedaquiline and delamanid in the management of MDR/XDR-TB
    Christian Lienhardt (Switzerland)